Bibliometric analysis of biomimetic drug delivery systems in China and abroadFU Li-xia, JIA Guo-shu, LIN Zhi-qiang, CUI Yi-min1521-1532
Clinical trial analysis of Medway——a recombinant human serum albuminWANG Yan-lin, RAO Ya-lan, YU Ai-ping, LU Shuang1539-1543
Considerations on species selection in non-clinical similarity assessment of biosimilars:an example of post-approval change of an infliximab biosimilarWANG Chen-guang, SUN Si-si, CHEN Xi-yuan1551-1556
Advances in Src homology 2 domain-containing protein tyrosine phosphatase inhibitors in tumor targeting and immunotherapySHI Ge-ge, WANG Zhao-wei, QIU Yue-yuan, HE Lei, LI Zhao-zhao, SHI Jia-xin, ZHAO Bo-chen, HAN Xiao, DU Hai-chen, ZHANG Ying-qi1557-1563
Research progress of nano-drug delivery system with intelligent control/response to tumor microenvironment for tumor therapyZOU Man-shu, LEI Chang, HUANG Dan, LIU Lan, HAN Yuan-shan1564-1570
Advances in drug delivery of small interfering RNA therapy for Alzheimer's diseaseZHANG Yao-yao, SU Feng, CAO Jun-ru, ZHANG Jun-li, HE Guang-wei, XU Yun-gen1571-1579
Construction of risk assessment index framework for clinical research in China based on Delphi methodZHANG Ai-yi, CHEN Hu, SHENG Ai-juan, BAI Nan, CHEN Yan-fen, YU Zhong-guang1580-1585
(Quantitative)structure-activity relationship to assess genotoxicity of parecoxib sodium-related substancesHU Yang, NIU Jian-zhao, GUAN Hao-yue1586-1594